SecBot SecBot
SECBOTREPLAY Home › Report › NRXP

NRXP · NRx Pharmaceuticals' subsidiary Hope Therapeutics partnered with Emobot…

NRx Pharmaceuticals, Inc. · PRESS-RELEASE filed Mar 30, 2026 at 07:00 ET

At the news

BULLISHIMPACT 6/10

PRESS-RELEASE filed Mar 30, 2026 at 07:00 ET

NRx Pharmaceuticals' subsidiary Hope Therapeutics partnered with Emobot Health to deploy an AI-powered 'Depression Thermometer' across its interventional psychiatry clinics. The technology enables passive, real-time monitoring of depression and anxiety via smartphone, aiming to reduce relapse rates and improve patient outcomes through early intervention.

  • Hope Therapeutics (NRXP subsidiary) partnered with Emobot Health to integrate AI-driven emotional monitoring in its clinic network.
  • Emobot's 'Depression Thermometer' passively analyzes facial expressions, vocal tones, and actigraphy to detect early relapse in TRD patients.
  • Clinical validation shows strong correlation with MADRS (r=0.89) and PHQ-9 (r=0.83) scales.
  • The platform aims to double patient success rates by enabling timely recapture interventions like maintenance ketamine or TMS.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access